)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Praxis Precision Medicines
Praxis Precision Medicines (PRAX) investor relations material
Praxis Precision Medicines Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary6 Aug, 2026
Mission and strategic vision
Focused on delivering life-altering treatments for CNS disorders with urgency and repeatability.
Aims to launch four CNS products with blockbuster potential by 2028, supported by a robust late-stage pipeline.
Projects a portfolio peak sales potential exceeding $20B, with cash runway into 2028.
Pipeline and innovation platforms
Pipeline includes ulixacaltamide (essential tremor), relutrigine (DEEs), elsunersen (early onset SCN2A DEE), and vormatrigine (epilepsy).
Utilizes Cerebrum™ (small molecule) and Solidus™ (ASO) platforms for precision CNS drug discovery.
Multiple programs have received Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations from FDA and EMA.
Clinical and commercial highlights
Ulixacaltamide demonstrated significant functional improvement in essential tremor, with positive Phase 3 results and PDUFA date in January 2027.
Relutrigine showed robust seizure reduction in DEEs, with NDA accepted and PDUFA in December 2026.
Elsunersen achieved marked seizure reduction in early onset SCN2A DEE, with ongoing pivotal trial.
Vormatrigine delivered best-in-disease efficacy in epilepsy, with broad applicability and favorable tolerability.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Praxis Precision Medicines
- $1.4B cash, late-stage FDA reviews, and commercial readiness drive 2027 launch plans.PRAX
Q2 2026 - Pivotal epilepsy studies and a robust pipeline set up multiple clinical catalysts through early 2026.PRAXJefferies Global Healthcare Conference 2025
- Accelerated clinical and regulatory strategies are driving earlier market entry for key therapies.PRAXFireside Chat
- All proposals, including director elections and auditor ratification, were approved by shareholders.PRAXAGM 2026
- Ulixacaltamide targets a vast unmet need in essential tremor, with a major launch imminent.PRAXGoldman Sachs 47th Annual Global Healthcare Conference 2026
- Ulyxa and relumitragene advance toward launch with strong FDA continuity and broad commercialization plans.PRAXTD Cowen 46th Annual Health Care Conference
- Two NDAs filed, strong clinical data, and $1.5B cash position support 2026 launches.PRAXQ4 2025
- Q3 net loss was $51.9M; $411.2M cash funds late-stage CNS trials into 2027 with key data in 2025.PRAXQ3 2024
- Multiple late-stage clinical readouts and $433.8M cash support operations into 2027.PRAXQ2 2024
Next Praxis Precision Medicines earnings date
Q3 20269 Nov, 2026
Praxis Precision Medicines
Next Praxis Precision Medicines earnings date
Q3 20269 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Praxis Precision Medicines Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders. The company leverages genetic insights and a precision medicine approach to develop treatments for conditions such as epilepsy, movement disorders, and psychiatric conditions. Praxis is dedicated to addressing unmet medical needs through targeted therapies aimed at neurological circuits and pathways that are implicated in various CNS diseases. Its pipeline includes a range of investigational treatments designed to offer new therapeutic options for patients with these complex conditions. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.